MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
// Cristian Taccioli 1, * , Giovanni Sorrentino 2, 3, * , Alessandro Zannini 2, 3 , Jimmy Caroli 1 , Domenico Beneventano 4 , Laura Anderlucci 5 , Marco Lolli 6 , Silvio Bicciato 1 , Giannino Del Sal 2, 3 1 Department of Life Sciences, University of Modena and Reggio Emilia, Modena 41125, Italy 2 Laboratorio Nazionale CIB (LNCIB), Area Science Park, Trieste 34149, Italy 3 Dipartimento di Scienze della Vita, Università degli Studi di Trieste, Trieste 34149, Italy 4 Dipartimento di Ingegneria “Enzo Ferrari”, Modena 41125, Italy 5 Dipartimento di Scienze Statistiche, Bologna 40124, Italy 6 Department of Science and Drug Technology, University of Torino, Torino 10125, Italy * These authors have contributed equally to this work Correspondence to: Silvio Bicciato, e-mail: silvio.bicciato@unimore.it Giannino Del Sal, e-mail: delsal@lncib.it Keywords: cancer, targeted therapy, Hippo pathway, small molecules, pharmacogenomics Received: August 10, 2015 Accepted: October 05, 2015 Published: October 15, 2015 ABSTRACT Targeted anticancer therapies represent the most effective pharmacological strategies in terms of clinical responses. In this context, genetic alteration of several oncogenes represents an optimal predictor of response to targeted therapy. Integration of large-scale molecular and pharmacological data from cancer cell lines promises to be effective in the discovery of new genetic markers of drug sensitivity and of clinically relevant anticancer compounds. To define novel pharmacogenomic dependencies in cancer, we created the Mutations and Drugs Portal (MDP, http://mdp.unimore.it ), a web accessible database that combines the cell-based NCI60 screening of more than 50,000 compounds with genomic data extracted from the Cancer Cell Line Encyclopedia and the NCI60 DTP projects. MDP can be queried for drugs active in cancer cell lines carrying mutations in specific cancer genes or for genetic markers associated to sensitivity or resistance to a given compound. As proof of performance, we interrogated MDP to identify both known and novel pharmacogenomics associations and unveiled an unpredicted combination of two FDA-approved compounds, namely statins and Dasatinib, as an effective strategy to potently inhibit YAP/TAZ in cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681 · cited 1×
“com/oncotarget benefit of such therapeutic intervention, tumours often recur in few months due to acquired drug resistance, which calls for urgent development of novel strategies to identify drugs for personalized therapies [41].”
BackgroundYang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J. A., Thompson, I. R., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1111 · Cited by 4,051
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788 · cited 3×
“MAPK cascade and its downstream kinase MEK (Mitogen-activated protein kinase) are activated by the Serine/Threonine Kinase RAF [17].”
BackgroundInfluentialStatins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Calvo, F., Ege, N., Grande-Garcia, A., Hooper, S., Jenkins, R. P., Chaudhry, S. I., Harrington, K., Williamson, P., Moeendarbary, E., Charras, G., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2756 · Cited by 1,478 · cited 1×
“Furthermore, it has been recently shown that in cancer associated fibroblasts, downstream of actomyosin cytoskeleton and mechanical stress, the kinase Src is functionally required for YAP activation and its inhibition by Dasatinib can efficiently block YAP nuclear functions [49].”
BackgroundThe Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells
Cordenonsi, M., Zanconato, F., Azzolin, L., Forcato, M., Rosato, A., Frasson, C., Inui, M., Montagner, M., Parenti, A. R., Poletti, A., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.048 · Cited by 1,381 · cited 2×
“The evidence that statin and Dasatinib, as demonstrated from our work, act synergistically to inhibit YAP/TAZ suggests that they could be used in combination and thus at lower concentrations, to inhibit YAP/TAZ activity and tumour growth in cancers characterised by hyperactivation of YAP/TAZ and, among them, in triple…”
BackgroundSelf-citationThe exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology
Abaan, O. D., Polley, E. C., Davis, S. R., Zhu, Y. J., Bilke, S., Walker, R. L., Pineda, M., Gindin, Y., Jiang, Y., Reinhold, W. C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3342 · Cited by 288
Cited by
Role of YAP/TAZ in cell-matrix adhesion-mediated signalling and mechanotransduction
Dupont, S. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.10.034 · Cited by 449
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
Statins: a repurposed drug to fight cancer
Jiang, W., Hu, J.-W., He, X.-R., Jin, W.-L., & He, X.-Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02041-2 · Cited by 417
Mechanobiology of Tumor Growth
Chaudhuri, P. K., Low, B. C., & Lim, C. T. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00042 · Cited by 192
TAZ and YAP are frequently activated oncoproteins in sarcomas
Fullenkamp, C. A., Hall, S. L., Jaber, O. I., Pakalniskis, B. L., Savage, E. C., Savage, J. M., Ofori-Amanfo, G. K., Lambertz, A. M., Ivins, S. D., Stipp, C. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8979 · Cited by 78
Metadata
- Authors
- Taccioli, C., Sorrentino, G., Zannini, A., Caroli, J., Beneventano, D., Anderlucci, L., Lolli, M., Bicciato, S., & Del Sal, G.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-10-15
- Volume
- 6
- Issue
- 36
- Pages
- 38854-38865
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2173710913
- Cited by
- 64
- References
- 7
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells. https://app.cochat.ai/papers/10.18632/oncotarget.5749
- The paper
- Taccioli, C., Sorrentino, G., Zannini, A., Caroli, J., Beneventano, D., Anderlucci, L., Lolli, M., Bicciato, S., & Del Sal, G. (2015). MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells. Oncotarget. https://doi.org/10.18632/oncotarget.5749
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.